Loading fund…
Loading fund…
| Returns | 1D | 1M | 3M | YTD | 1Y | 3Y | 5Y | MAX |
|---|---|---|---|---|---|---|---|---|
| Total return | ▼ −0.6% | ▲ +0.8% | ▲ +4.3% | ▲ +22.0% | ▲ +37.4% | ▲ +98.1% | — | ▲ +79.0% |
| Peer average | — | — | — | — | — | — | — | — |
| S&P 500 · VOO | ▼ −0.4% | ▲ +0.9% | ▲ +3.3% | ▲ +13.8% | ▲ +13.3% | ▲ +88.8% | ▲ +81.9% | — |
The Tema Oncology ETF (CANC) is designed to strategically invest in companies well-positioned to capitalize on significant advancements within cancer-focused biotechnology and the broader healthcare sector.
Distribution yield and SEC yield use different methodologies. Payouts may include income, capital gains, or return of capital.
| Ex-date | Pay date | Per share |
|---|---|---|
| 2025-12-10 | 2025-12-11 | $0.02 |
| 2024-12-11 | 2024-12-12 | $0.73 |
| 2023-12-13 | 2023-12-15 | $0.15 |
Estimated annual expense excludes trading costs and assumes constant assets. Fee waivers and fund costs can change.
Historical risk measures describe past behavior and do not predict future returns.
Hear the strategy from the people behind CANC.